Pharmaceutical composition for preparing drug delivery nano/micro bubbles

Patent metadata

Field	Value
Publication number	US-2016015629-A1
Application number	US-201414556740-A
Country	US
Kind code	A1
Filing date	Dec 1, 2014
Priority date	Jul 18, 2014
Publication date	Jan 21, 2016
Grant date	—

Abstract

The pharmaceutical composition includes a drug layer comprising an active ingredient, a surfactant, an acidic component and an effervescent ingredient. The active ingredient comprises a nucleic acid, a peptide or a protein. The acidic component and effervescent ingredient of the drug layer are dissolved in the water to react for generating carbon dioxide and bubbles thereof. The surfactants surround the carbon dioxide gas core and form a double-layer structure having an inner layer and outer layer. The active ingredient is embedded in a gap formed between the inner layer and the outer layer of the double-layer structure.

First claim

What is claimed is:

1 . A pharmaceutical composition for preparing drug delivery bubbles, comprising:
a drug layer comprising:
an active ingredient comprising a nucleic acid, a peptide or a protein,
a surfactant,
an acidic component and
an effervescent ingredient, whereby the acidic component and effervescent ingredient of the drug layer are dissolved in the water to react for generating carbon dioxide and bubbles thereof, the surfactants surround the carbon dioxide gas core and form a double-layer structure having an inner layer and outer layer and the active ingredient is embedded in a gap formed between the inner layer and the outer layer of the double-layer structure.

2 . The pharmaceutical composition according to claim 1 , wherein the pharmaceutical composition is a tablet or a capsule.

3 . The pharmaceutical composition according to claim 1 , wherein the surfactant comprises an anionic surfactant, a cationic surfactant, an amphoteric surfactant or a non-ionic surfactant.

4 . The pharmaceutical composition according to claim 1 , wherein the surfactants comprise sodium dodecyl sulfate, polyoxyethylene sorbitan monostearate, sodium laureth sulfate or sodium dodecyl benzene sulfonate.

5 . The pharmaceutical composition according to claim 1 , wherein the effervescent ingredient comprises a carbonate or a bicarbonate.

6 . The pharmaceutical composition according to claim 1 , wherein the acidic ingredient comprises an organic acid or an inorganic acid.

7 . The pharmaceutical composition according to claim 1 , wherein the acidic ingredient comprises diethylenetriaminepentaacetic dianhydride (DTPA anhydride).

8 . The pharmaceutical composition according to claim 1 , wherein the active ingredient comprises insulin, erythropoietin, somatotropin, platelet derived growth factor, epidermal growth factor, transforming growth factor α, transforming growth factor β, epidermal growth factor, fibroblast growth factor, nerve growth factor, insulin-like growth factor I, insulin-like growth factor II, clotting Factor VIII, superoxide dismutase, α-interferon, γ-interferon, interleukin-1, interleukin-2, interleukin-3, interleukin-4, interleukin-5, interleukin-6, granulocyte colony stimulating factor, granulocyte-macrophage stimulating factor or macrophage colony stimulating factor.

9 . The pharmaceutical composition according to claim 1 , further comprising a gelatin layer, wherein the drug layer is coated with the gelatin layer.

10 . The pharmaceutical composition according to claim 1 , further comprising an enteric layer, wherein the drug layer is coated with the enteric layer.

11 . The pharmaceutical composition according to claim 10 , wherein the enteric coating layer comprises (methyl) acrylic acid copolymer, hydroxypropyl cellulose phthalate ester, hydroxypropyl cellulose acetate ester, hydroxypropyl cellulose acetate succinate ester or carboxymethyl ethyl cellulose.

12 . The pharmaceutical composition according to claim 1 , wherein the drug layer further comprises a release controlling component.

13 . The pharmaceutical composition according to claim 1 , wherein the pharmaceutical composition is an oral pharmaceutical composition.

14 . The pharmaceutical composition according to claim 1 , wherein the active ingredient is an insulin.

Assignees

• Nat Univ Tsing Hua

Inventors

• Sung Hsing-Wen
• Chuang Er-Yuan
• Lin Po-Yen

Classifications

• A61K9/4891

  Coated capsules; Multilayered drug free capsule shells (with drug coating for immediate release A61K9/4808; osmotic devices A61K9/0004) · CPC title

• A61K9/4858

  Organic compounds · CPC title

• A61K9/0007 Primary

  Effervescent (A61K9/0065 takes precedence) · CPC title

• A61K38/28

  Insulins · CPC title

• A61K9/5169

  Proteins, e.g. albumin, gelatin · CPC title